文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

长达十年的白血病缓解期与 CD4 CAR T 细胞的持续存在。

Decade-long leukaemia remissions with persistence of CD4 CAR T cells.

机构信息

Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

Nature. 2022 Feb;602(7897):503-509. doi: 10.1038/s41586-021-04390-6. Epub 2022 Feb 2.


DOI:10.1038/s41586-021-04390-6
PMID:35110735
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9166916/
Abstract

The adoptive transfer of T lymphocytes reprogrammed to target tumour cells has demonstrated potential for treatment of various cancers. However, little is known about the long-term potential and clonal stability of the infused cells. Here we studied long-lasting CD19-redirected chimeric antigen receptor (CAR) T cells in two patients with chronic lymphocytic leukaemia who achieved a complete remission in 2010. CAR T cells remained detectable more than ten years after infusion, with sustained remission in both patients. Notably, a highly activated CD4 population emerged in both patients, dominating the CAR T cell population at the later time points. This transition was reflected in the stabilization of the clonal make-up of CAR T cells with a repertoire dominated by a small number of clones. Single-cell profiling demonstrated that these long-persisting CD4 CAR T cells exhibited cytotoxic characteristics along with ongoing functional activation and proliferation. In addition, longitudinal profiling revealed a population of gamma delta CAR T cells that prominently expanded in one patient concomitant with CD8 CAR T cells during the initial response phase. Our identification and characterization of these unexpected CAR T cell populations provide novel insight into the CAR T cell characteristics associated with anti-cancer response and long-term remission in leukaemia.

摘要

经基因重定向以识别肿瘤细胞的 T 淋巴细胞过继转移已被证明具有治疗多种癌症的潜力。然而,对于输注细胞的长期潜在性和克隆稳定性知之甚少。在这里,我们研究了两名在 2010 年获得完全缓解的慢性淋巴细胞白血病患者中持久性的 CD19 重定向嵌合抗原受体 (CAR) T 细胞。输注后超过十年仍可检测到 CAR T 细胞,两名患者均持续缓解。值得注意的是,两名患者均出现高度活化的 CD4 群体,在后期主导 CAR T 细胞群体。这种转变反映在 CAR T 细胞克隆组成的稳定上,其特征是由少数克隆主导的丰富谱。单细胞分析表明,这些长期存在的 CD4 CAR T 细胞具有细胞毒性特征,同时伴有持续的功能激活和增殖。此外,纵向分析显示,在一名患者中,与 CD8 CAR T 细胞同时,γδ CAR T 细胞的一个亚群在初始反应阶段显著扩增。我们对这些意外的 CAR T 细胞群体的鉴定和特征分析为白血病中与抗癌反应和长期缓解相关的 CAR T 细胞特征提供了新的见解。

相似文献

[1]
Decade-long leukaemia remissions with persistence of CD4 CAR T cells.

Nature. 2022-2

[2]
CD19 CAR T cell product and disease attributes predict leukemia remission durability.

J Clin Invest. 2019-3-12

[3]
In Vivo Generation of CAR T Cells Selectively in Human CD4 Lymphocytes.

Mol Ther. 2020-8-5

[4]
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.

Lancet Haematol. 2020-11

[5]
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.

J Clin Oncol. 2020-11-10

[6]
Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.

Front Immunol. 2020

[7]
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy.

Nat Commun. 2020-1-10

[8]
Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.

Int J Cancer. 2021-1-15

[9]
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.

Lancet Haematol. 2021-10

[10]
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.

Lancet Oncol. 2023-11

引用本文的文献

[1]
[Long-term follow up of efficiency and safety of CD19-CAR T-cell treatment of systemic lupus erythematosus].

Z Rheumatol. 2025-9-4

[2]
Engineering strategies of sequential drug delivery systems for combination tumor immunotherapy.

Acta Pharm Sin B. 2025-8

[3]
CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon.

Front Immunol. 2025-8-12

[4]
Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells.

Nat Biomed Eng. 2025-8-25

[5]
Direct visualization of chimeric antigen receptors on primary human T cells using STORM super-resolution microscopy.

Front Immunol. 2025-8-1

[6]
A multi-scale semi-mechanistic CK/PD model for CAR T-cell therapy.

Front Syst Biol. 2024-8-29

[7]
Precision-cut tumor tissue slices, a novel tool to study the tumor microenvironment interactions with chimeric antigen receptor (CAR) T cells.

PLoS One. 2025-8-8

[8]
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies.

NPJ Digit Med. 2025-8-1

[9]
Targeting CD276 with Adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide.

J Hematol Oncol. 2025-7-28

[10]
CAR-iNKT cells: redefining the frontiers of cellular immunotherapy.

Front Immunol. 2025-7-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索